BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37598177)

  • 1. HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis.
    Di Agostino S; Canu V; Donzelli S; Pulito C; Sacconi A; Ganci F; Valenti F; Goeman F; Scalera S; Rollo F; Bagnato A; Diodoro MG; Vizza E; Carosi M; Rufini B; Federici O; Giofrè M; Carboni F; Muti P; Ciliberto G; Strano S; Valle M; Blandino G
    Cell Death Dis; 2023 Aug; 14(8):535. PubMed ID: 37598177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peritoneal Fluid Analysis of Advanced Ovarian Cancers after Hyperthermic Intraperitoneal Chemotherapy.
    Chen WC; Chang TC; Chou HH; Cheng MH; Hong JJ; Hsieh YS; Cheng CM
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels.
    Zhang M; Bao Y; Zhang H; Li D; Mei X; Cheng X
    J Obstet Gynaecol; 2023 Dec; 43(1):2204940. PubMed ID: 37186893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision-Making Analysis for Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: A Survey by the Executive Committee of the Peritoneal Surface Oncology Group International (PSOGI).
    Steffen T; Häller L; Bijelic L; Glatzer M; Glehen O; Goéré D; de Hingh I; Li Y; Moran BJ; Morris DL; Piso P; Quadros CA; Rau B; Sugarbaker P; Yonemura Y; Putora PM
    Oncology; 2021; 99(1):41-48. PubMed ID: 32920557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
    Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
    Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
    Sugarbaker PH; Stuart OA
    Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.
    Dellinger TH; Han ES; Raoof M; Lee B; Wu X; Cho H; He TF; Lee P; Razavi M; Liang WS; Schmolze D; Priceman SJ; Lee S; Lin WC; Lin JF; Kebria M; Hakim A; Ruel N; Stewart DB; Wang EW; Paz BI; Wakabayashi MT; Cristea MC; Rodriguez-Rodriguez L
    JCO Precis Oncol; 2022 Mar; 6():e2100239. PubMed ID: 35357903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review.
    van Stein RM; Aalbers AGJ; Sonke GS; van Driel WJ
    JAMA Oncol; 2021 Aug; 7(8):1231-1238. PubMed ID: 33956063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues.
    Moukarzel LA; Ferrando L; Dopeso H; Stylianou A; Basili T; Pareja F; Da Cruz Paula A; Zoppoli G; Abu-Rustum NR; Reis-Filho JS; Long Roche K; Tew WP; Chi DS; Sonoda Y; Zamarin D; Aghajanian C; O'Cearbhaill RE; Zivanovic O; Weigelt B
    Gynecol Oncol; 2022 May; 165(2):239-247. PubMed ID: 35292180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant Struma Ovarii Τreated With Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Acs M; Häusler S; Lighvani HR; Zustin J; Piso P
    In Vivo; 2021; 35(6):3591-3596. PubMed ID: 34697200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
    El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
    ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
    Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.
    Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH
    Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA Repair Pathway in Ovarian Cancer Patients Treated with HIPEC.
    Flasarova D; Urban K; Strouhal O; Klos D; Lemstrova R; Dvorak P; Soucek P; Mohelnikova-Duchonova B
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and management of incisional hernia after cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal surface malignancies.
    Cascales Campos PA; González-Gil A; Gómez-Ruiz AJ; Gil-Gómez E; Alconchel-Gago F; Navarro-Barrios A; Martínez-García J; Alonso-Romero JL; Nieto A; Barceló-Valcarcel F; Gil-Martínez J
    Hernia; 2020 Apr; 24(2):257-263. PubMed ID: 31069579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
    Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma.
    Lopez-Ramirez F; Sardi A; Studeman K; King MC; Falla-Zuniga LF; Nikiforchin A; Baron E; Nieroda C; Gushchin V; Diaz-Montes T
    Eur J Surg Oncol; 2023 Aug; 49(8):1495-1503. PubMed ID: 37068984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.